~~<i id='B67864C12A'><strike id='B67864C12A'><tt id='B67864C12A'><pre id='B67864C12A'></pre></tt></strike></i>~~

00:00

00:00 00:00 LIVE

buffering

Replay

focus

comprehensive

author：entertainment 2025-09-29 09:55:06 - browse：5

Eli Lilly said Friday that it will acquire Dermira, a small biotech developing drugs for chronic skin conditions, for $1.1 billion.

The centerpiece of the deal is the Dermira drug called lebrikizumab that aims to treat people suffering from moderate-to-severe atopic dermatitis, the most common form of eczema, a disease characterized by inflamed, itchy, and scaly skin.

Phase 3 clinical trials of lebrikizumab in atopic dermatitis are underway. If successful, the drug could compete against Dupixent, which has grown into a commercial blockbuster for Regeneron Pharmaceuticals and Sanofi.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： ChatGPT in medicine: STAT answers readers' burning questions
Next article： New Alzheimer's drugs heat up race for early detection blood tests

explore

leisure time

entertainment

Wikipedia

leisure time

AdobeMattFitzgeraldusedtobikeupanddown3,500feetthroughtheSantaAnaMountainsonthree-hourridesjustforfu

WSS

What don’t we know about an Alzheimer’s drug side effect?

CDC Director Mandy Cohen on transparency, trust, and health

In the gardens at Boston Children's Hospital, families find sanctuary

How to pay for weight loss drugs and save Medicare

Rise in cancer among younger people worries and puzzles doctors

Organ aging and disease risk measured by new blood test

focus

comprehensive

explore

The high cost of giving birth even with insurance

What it's like to live with paralysis for one psychologist

Medical records are filled with copy

Disappointing trial forces Pfizer to pivot on obesity medicine plans

The cancer drug shortage isn’t new — and neither are the solutions

Rise in cancer among younger people worries and puzzles doctors

Tori Bowie and the unacceptable rates of Black maternal death

Device maker Teleflex to acquire urology company for $600M

How to save PrEP access — and even expand it

Why patients can’t get everything they want on drug pricing

leisure time

30 years of 'Listening to Prozac'

With clinical trial data readouts, here's how to spot spin

U.K. Biobank has 500,000 peoples' genome sequences available

How doctors’ personal politics affect patients

The battle over 'scope creep' and who gets to be called 'doctor'

Cigna, Humana reportedly in talks to merge

entertainment

Wikipedia

leisure time

leisure time